Company profile: Angiex
1.1 - Company Overview
Company description
- Provider of vascular-targeted biotherapeutics, developing TM4SF1-directed antibody-drug conjugates for solid tumors, including AGX101, an antibody–microtubule inhibitor conjugate entering Phase 1 to target tumor cells and tumor vascular endothelium; a Nuclear Delivery Platform with antibodies, site-specific conjugation, and linkers for nucleus/cytosol delivery; and a preclinical ND-ADC pipeline using small molecule and protein degrader payloads.
Products and services
- Nuclear Delivery Platform: Proprietary platform using TM4SF1-directed antibodies, site-specific conjugation, and optimized linkers to deliver drug payloads directly to tumor cell nuclei or cytosol, improving efficacy and safety
- AGX101: Clinical-stage TM4SF1-directed antibody–microtubule inhibitor conjugate entering Phase 1, engineered to treat solid tumors by targeting tumor cells and tumor vascular endothelium for dual anti-cancer activity
- Preclinical Pipeline: Discovery-stage diverse ND-ADCs portfolio utilizing small molecule and protein degrader payloads aimed at treating solid cancers.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Angiex
Ajax Therapeutics
HQ: United States
Website
- Description: Provider of therapies targeting cytokine signaling in hematologic malignancies, including AJ1-10502, a next-generation Type II JAK2 inhibitor for myeloproliferative neoplasms with improved efficacy and selectivity over Type I JAK2 inhibitors, and developer of a pipeline of selectively targeted small molecules via a partnership with Schrödinger using advanced computational chemistry and structure-based technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ajax Therapeutics company profile →
Carrick Therapeutics
HQ: Ireland
Website
- Description: Provider of cancer therapeutics targeting molecular pathways driving aggressive and resistant cancers. Pipeline includes Samuraciclib (CT7001), an oral CDK7 inhibitor in clinical development for HR+, HER2- advanced breast cancer and triple negative breast cancer, and a CDK12/13 inhibitor/Cyclin-K glue-degrader in IND enabling toxicology studies targeting genomic stability and DNA repair.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Carrick Therapeutics company profile →
Progenics Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics for cancer and related conditions, developing PSMA-targeted radioligand therapies (PNT2002, LNTH-1095), diagnostic imaging agents (LNTH-1404), and antibodies (PSMA-TAC), plus a somatostatin receptor-targeted radioligand therapy (PNT2003) for neuroendocrine tumors, alongside pipeline candidates such as PSMA ADC and LNTH-1558 in various clinical and preclinical stages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Progenics Pharmaceuticals company profile →
Sorrento Therapeutics
HQ: United States
Website
- Description: Provider of proprietary drug therapeutics under development to address unmet medical needs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sorrento Therapeutics company profile →
Immunovia
HQ: Sweden
Website
- Description: Provider of blood-based diagnostics for early detection of pancreatic cancer, conducting clinical trials and validation studies to ensure accuracy and reliability, and collaborating with medical institutions and research centers globally to validate its diagnostic tests and bring them to market.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunovia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Angiex
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Angiex
2.2 - Growth funds investing in similar companies to Angiex
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Angiex
4.2 - Public trading comparable groups for Angiex
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →